Clene vs Lisata Therapeutics
Clene reported revenue of $0 million in fiscal 2025, about the same as Lisata Therapeutics' $0 million in fiscal 2025. Clene's revenue fell 41.5% in its latest year, and Lisata Therapeutics' fell 83.0%. Clene had an operating margin of -11541.5%, against -10711.2% at Lisata Therapeutics. Free cash flow was −$19 million at Clene and −$16 million at Lisata Therapeutics.
Side by side
| Clene | Lisata Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | −41.5% | −83.0% |
| Revenue growth a year, last 5 years | 0.0% | — |
| Gross margin | 78.5% | — |
| Operating margin | −11,541.5% | −10,711.2% |
| Net margin | −13,086.5% | −9,756.5% |
| Free cash flow | −$19M | −$16M |
| Free cash flow margin | −9,292.5% | −9,398.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 41.8% | 4.3% |
| Last close | $3.50 | $0.91 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $250,904, sold $5.8 million | — |
| Piotroski F-score | 2 of 9 | 1 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CleneLisata Therapeutics
Operating margin
Percent of revenue
CleneLisata Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CleneLisata Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Clene and Lisata Therapeutics pages.